Development of extracellular signal-regulated kinase inhibitors

Current Topics in Medicinal Chemistry

Volumn 9, Issue 8, 2009, Pages 678-689

  Burkhard, Kimberly ^a   Smith, Sarice ^a   Deshmukh, Rahul ^a   MacKerell Jr , Alexander D ^a   Shapiro, Paul ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Computer aided drug design; Docking domains; Extracellular signal regulated kinase; Mitogen activated protein kinases; Signal transduction

Indexed keywords

ADENOSINE TRIPHOSPHATE; FR 148083; FR 180204; G PROTEIN COUPLED RECEPTOR; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHENYLALANINE; PROTEIN TYROSINE KINASE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BINDING AFFINITY; BINDING SITE; CELL ASSAY; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPUTER AIDED DESIGN; COMPUTER AIDED DRUG DESIGN; COMPUTER MODEL; DRUG ACTIVITY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENTROPY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; FLUORESCENCE; HIGH THROUGHPUT SCREENING; IC 50; INFLAMMATION; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR WEIGHT; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REVIEW; SPECTROSCOPY; SURFACE PLASMON RESONANCE; THERMODYNAMICS; THREE DIMENSIONAL IMAGING;

ADENOSINE TRIPHOSPHATE; ANIMALS; DRUG DESIGN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350131897     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789044416     Document Type: Review

References (102)

1. Lewis, T. S.; Shapiro, P. S.; Ahn, N. G. Signal tranduction through MAP kinase cascades. Adv. Cancer Res. 1998, 74, 49-139.
2. Cobb, M. H.; Goldsmith, E. J. How MAP kinases are regulated. J. Biol. Chem. 1995, 270, 14843-14846.
3. Pearson, G.; Robinson, F.; Gibson, T. B.; Xu, B. E.; Karandikar, M.; Berman, K.; Cobb, M. H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 2001, 22, 153-183.
4. Nishimoto, S.; Nishida, E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep. 2006, 7, 782-786.
5. Raman, M.; Chen, W.; Cobb, M. H. Differential regulation and properties of MAPKs. Oncogene 2007, 26, 3100-3112.
6. Schett, G.; Zwerina, J.; Firestein, G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann. Rheum. Dis. 2008, 67, 909-916.
7. Adcock, I. M.; Caramori, G.; Chung, K. F. New targets for drug development in asthma. Lancet 2008, 372, 1073-1087.
8. Ivanenkov, Y. A.; Balakin, K. V.; Tkachenko, S. E. New approaches to the treatment of inflammatory disease: Focus on small-molecule inhibitors of signal transduction pathways. Drugs R. D. 2008, 9, 397-434.
9. Pettus, L. H.; Wurz, R. P. Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: Novel structures and developments during 2006-2008. Curr. Top. Med. Chem. 2008, 8, 1452-1467.
10. Thalhamer, T.; McGrath, M. A.; Harnett, M. M. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47, 409-414.
11. Hallett, J. M.; Leitch, A. E.; Riley, N. A.; Duffin, R.; Haslett, C.; Rossi, A. G. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. Trends Pharmacol. Sci. 2008, 29, 250-257.
12. Pages, G.; Guerin, S.; Grall, D.; Bonino, F.; Smith, A.; Anjuere, F.; Auberger, P.; Pouyssegur, J. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999, 286, 1374-1377.
13. Reuter, C. W.; Morgan, M. A.; Bergmann, L. Targeting the Ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies? Blood 2000, 96, 1655-1669.
14. Brose, M. S.; Volpe, P.; Feldman, M.; Kumar, M.; Rishi, I.; Gerrero, R.; Einhorn, E.; Herlyn, M.; Minna, J.; Nicholson, A.; Roth, J. A.; Albelda, S. M. Davies, H.; Cox, C.; Brignell, G.; Stephens, P.; Futreal, P. A.; Wooster, R.; Stratton, M. R.; Weber, B L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002, 62, 6997-7000.
15. Bos, J. L. Ras oncogenes in human cancer: A review. Cancer Res. 1989, 49, 4682-4689.
16. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949-954.
17. Mendelsohn, J.; Baselga, J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 2006, 33, 369-385.
18. Kolch, W.; Kotwaliwale, A.; Vass, K.; Janosch, P. The role of Raf kinases in malignant transformation. Expert Rev. Mol. Med. 2002, 4, 1-18.
19. Murphy, L. O.; Smith, S.; Chen, R. H.; Fingar, D. C.; Blenis, J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 2002, 4, 556-564.
20. Willems, A.; Gauger, K.; Henrichs, C.; Harbeck, N. Antibody therapy for breast cancer. Anticancer Res. 2005, 25, 1483-1489.
21. Arora, A.; Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 2005, 315, 971-979.
22. Appels, N. M.; Beijnen, J. H.; Schellens, J. H. Development of farnesyl transferase inhibitors: A review. Oncologist 2005, 10, 565-578.
23. Lowinger, T. B.; Riedl, B.; Dumas, J.; Smith, R. A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharm. Des. 2002, 8, 2269-2278.
24. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64, 7099-7109.
25. Friday, B. B.; Adjei, A. A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 2008, 14, 342-346.
26. Liao, J. J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem. 2007, 50, 409-424.
27. Levitzki, A. Tyrosine kinases as targets for cancer therapy. Eur. J. Cancer 2002, 38 (Suppl 5), S11-S18.
28. Nolen, B.; Taylor, S.; Ghosh, G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 2004, 15, 661-675.
29. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128.
30. Vieth, M.; Higgs, R. E.; Robertson, D. H.; Shapiro, M.; Gragg, E. A.; Hemmerle, H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 2004, 1697, 243-257.
31. Yang, S. H.; Whitmarsh, A. J.; Davis, R. J.; Sharrocks, A. D. Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. EMBO J. 1998, 17, 1740-1749.
32. Yang, S. H.; Yates, P. R.; Whitmarsh, A. J.; Davis, R. J.; Sharrocks, A. D. The Elk-1 ETS-domain transcription factor contains a mitogen-activated protein kinase targeting motif. Mol. Cell Biol. 1998, 18, 710-720.
33. Galanis, A.; Yang, S. H.; Sharrocks, A. D. Selective targeting of MAPKs to the ETS domain transcription factor SAP-1. J. Biol. Chem. 2001, 276, 965-973.
34. Sharrocks, A. D.; Yang, S. H.; Galanis, A. Docking domains and substrate-specificity determination for MAP kinases. Trends Biochem. Sci. 2000, 25, 448-453.
35. Bardwell, L.; Thorner, J. A conserved motif at the amino termini of MEKs might mediate high-affinity interaction with the cognate MAPKs. Trends Biochem. Sci. 1996, 21, 373-374.
36. Xu, B.; Wilsbacher, J. L.; Collisson, T.; Cobb, M. H. The N-terminal ERK-binding site of MEK1 is required for efficient feedback phosphorylation by ERK2 in vitro and ERK activation in vivo. J. Biol. Chem. 1999, 274, 34029-34035.
37. Smith, J. A.; Poteet-Smith, C. E.; Malarkey, K.; Sturgill, T. W. Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo. J. Biol. Chem. 1999, 274, 2893-2898.
38. Zuniga, A.; Torres, J.; Ubeda, J.; Pulido, R. Interaction of mitogen-activated protein kinases with the kinase interaction motif of the tyrosine phosphatase PTP-SL provides substrate specificity and retains ERK2 in the cytoplasm. J. Biol. Chem. 1999, 274, 21900-21907.
39. Johnson, T. R.; Biggs, J. R.; Winbourn, S. E.; Kraft, A. S. Regulation of dual-specificity phosphatases M3/6 and hVH5 by phorbol esters. Analysis of a delta-like domain. J. Biol. Chem. 2000, 275, 31755-31762.
40. Nichols, A.; Camps, M.; Gillieron, C.; Chabert, C.; Brunet, A.; Wilsbacher, J.; Cobb, M.; Pouyssegur, J.; Shaw, J. P.; Arkinstall, S. Substrate recognition domains within extracellular signal-regulated kinase mediate binding and catalytic activation of mitogen-activated protein kinase phosphatase-3. J. Biol. Chem. 2000, 275, 24613-24621.
41. Karin, M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 1995, 270, 16483-16486
42. Fantz, D. A.; Jacobs, D.; Glossip, D.; Kornfeld, K. Docking sites on substrate proteins direct extracellular signal-regulated kinase to phosphorylate specific residues. J. Biol. Chem. 2001, 276, 27256-27265.
43. Jacobs, D.; Beitel, G. J.; Clark, S. G.; Horvitz, H. R.; Kornfeld, K. Gain-of-function mutations in the Caenorhabditis elegans lin-1 ETS gene identify a C-terminal regulatory domain phosphorylated by ERK MAP kinase. Genetics 1998, 149, 1809-1822.
44. Tanoue, T.; Adachi, M.; Moriguchi, T.; Nishida, E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol. 2000, 2, 110-116.
45. Tanoue, T.; Maeda, R.; Adachi, M.; Nishida, E. Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions. EMBO J. 2001, 20, 466-479.
46. Callaway, K.; Abramczyk, O.; Martin, L.; Dalby, K. N. The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site. Biochemistry 2007, 46, 9187-9198.
47. Tanoue, T.; Nishida, E. Docking interactions in the mitogen-activated protein kinase cascades. Pharmacol. Ther. 2002, 93, 193-202.
48. Zhang, J.; Zhou, B.; Zheng, C. F.; Zhang, Z. Y. A bipartite mechanism for ERK2 recognition by its cognate regulators and substrates. J. Biol. Chem. 2003, 278, 29901-29912.
49. Martin, M. C.; Allan, L. A.; Mancini, E. J.; Clarke, P. R. The docking interaction of caspase-9 with ERK2 provides a mechanism for the selective inhibitory phosphorylation of caspase-9 at threonine 125. J. Biol. Chem. 2008, 283, 3854-3865.
50. Lee, T.; Hoofnagle, A. N.; Kabuyama, Y.; Stroud, J.; Min, X.; Goldsmith, E. J.; Chen, L.; Resing, K. A.; Ahn, N. G. Docking motif interactions in MAP kinases revealed by hydrogen exchange mass spectrometry. Mol. Cell 2004, 14, 43-55.
51. Jackson, P. F.; Bullington, J. L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem. 2002, 2, 1011-1020.
52. Gohlke, H.; Klebe, G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew. Chem. Int. Ed. Engl. 2002, 41, 2644-2676.
53. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9, 268-272.
54. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J. Med. Chem. 2002, 45, 2994-3008.
55. Hancock, C. N.; Macias, A.; Lee, E. K.; Yu, S. Y.; Mackerell, A. D. Jr.; Shapiro, P. Identification of novel extracellular signal-regulated kinase docking domain inhibitors. J. Med. Chem. 2005, 48, 4586-4595.
56. Davidson, W.; Frego, L.; Peet, G. W.; Kroe, R. R.; Labadia, M. E.; Lukas, S. M.; Snow, R. J.; Jakes, S.; Grygon, C. A.; Pargellis, C.; Werneburg, B. G. Discovery and characterization of a substrate selective p38alpha inhibitor. Biochemistry 2004, 43, 11658-11671.
57. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
58. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: An update. Biochem. J. 2003, 371, 199-204.
59. Fabian, M. A.; Biggs, W. H. 3rd; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
60. Ohori, M.; Kinoshita, T.; Okubo, M.; Sato, K.; Yamazaki, A.; Arakawa, H.; Nishimura, S.; Inamura, N.; Nakajima, H.; Neya, M.; Miyake, H.; Fujii, T. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem. Biophys. Res. Commun. 2005, 336, 357-363.
61. Ohori, M. ERK inhibitors as a potential new therapy for rheumatoid arthritis. Drug News Perspect. 2008, 21, 245-250
62. Ohori, M.; Kinoshita, T.; Yoshimura, S.; Warizaya, M.; Nakajima, H.; Miyake, H. Role of a cysteine residue in the active site of ERK and the MAPKK family. Biochem. Biophys. Res. Commun. 2007, 353, 633-637.
63. Aronov, A. M.; Baker, C.; Bemis, G. W.; Cao, J.; Chen, G.; Ford, P. J.; Germann, U. A.; Green, J.; Hale, M. R.; Jacobs, M.; Janetka, J. W.; Maltais, F.; Martinez-Botella, G.; Namchuk, M. N.; Straub, J.; Tang, Q.; Xie, X. Flipped out: Structure-guided design of selective pyrazolylpyrrole ERK inhibitors. J. Med. Chem. 2007, 50, 1280-1287.
64. Katayama, N.; Orita, M.; Yamaguchi, T.; Hisamichi, H.; Kuromitsu, S.; Kurihara, H.; Sakashita, H.; Matsumoto, Y.; Fujita, S.; Niimi, T. Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors. Proteins 2008, 73, 795-801.
65. Cochran, A. G. Protein-protein interfaces: Mimics and inhibitors. Curr. Opin. Chem. Biol. 2001, 5, 654-659.
66. Cochran, A. G. Antagonists of protein-protein interactions. Chem. Biol. 2000, 7, R85-94.
67. Zhong, S.; Macias, A. T.; MacKerell, A. D. Jr. Computational identification of inhibitors of protein-protein interactions. Curr. Top. Med. Chem. 2007, 7, 63-82.
68. Cody, W. L.; Lin, Z.; Panek, R. L.; Rose, D. W.; Rubin, J. R. Progress in the development of inhibitors of SH2 domains. Curr. Pharm. Des. 2000, 6, 59-98.
69. Garcia-Echeverria, C. Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70. Curr. Med. Chem. 2001, 8, 1589-1604.
70. Huang, N.; Nagarsekar, A.; Xia, G.; Hayashi, J.; MacKerell, A. D. Jr. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site. J. Med. Chem. 2004, 47, 3502-3511.
71. Enyedy, I. J.; Ling, Y.; Nacro, K.; Tomita, Y.; Wu, X.; Cao, Y.; Guo, R.; Li, B.; Zhu, X.; Huang, Y.; Long, Y. Q.; Roller, P. P.; Yang, D.; Wang, S. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. 2001, 44, 4313-4324.
72. Zhong, S.; MacKerell, A. D. Jr. Binding response: A descriptor for selecting ligand binding site on protein surfaces. J. Chem. Inf. Model 2007, 47, 2303-2315.
73. Pan, Y.; Huang, N.; Cho, S.; MacKerell, A. D. Jr. Consideration of molecular weight during compound selection in virtual target-based database screening. J. Chem. Inf. Comput. Sci. 2003, 43, 267-272.
74. Chen, I. J.; Neamati, N.; MacKerell, A. D. Jr. Structure-based inhibitor design targeting HIV-1 integrase. Curr. Drug Targets Infect. Disord. 2002, 2, 217-234.
75. Chen, F.; Hancock, C. N.; Macias, A. T.; Joh, J.; Still, K.; Zhong, S.; MacKerell, A. D. Jr.; Shapiro, P. Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorg. Med. Chem. Lett. 2006, 16, 6281-6287.
76. Westbrook, J.; Feng, Z.; Jain, S.; Bhat, T. N.; Thanki, N.; Ravichandran, V.; Gilliland, G. L.; Bluhm, W.; Weissig, H.; Greer, D. S.; Bourne, P. E.; Berman, H. M. The Protein Data Bank: Unifying the archive. Nucleic Acids Res. 2002, 30, 245-248.
77. Zhang, F.; Strand, A.; Robbins, D.; Cobb, M. H.; Goldsmith, E. J. Atomic structure of the MAP kinase ERK2 at 2.3 A resolution see comments. Nature 1994, 367, 704-711.
78. Canagarajah, B. J.; Khokhlatchev, A.; Cobb, M. H.; Goldsmith, E. J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 1997, 90, 859-869.
79. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
80. Kuntz, I. D. Structure-based strategies of drug discovery and design. Science 1992, 257, 1078-1082.
81. Huang, N.; Nagarsekar, A.; Xia, G.; Hayashi, J.; MacKerell, A. D. Jr. Identification of inhibitors targeting the pY+3 binding site of the tyrosine kinase p53lck SH2 domain. J. Med. Chem. 2004, 47, 3502-3511.
82. Opera, T. I. Property distribution of drug-related chemical databases. J. Comput.-Aided Mol. Des. 2000, 14, 251-264.
83. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comp. Sci. 2001, 41, 1308-1315.
84. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
85. Chen, F.; Mackerell, A. D. Jr.; Luo, Y.; Shapiro, P. Using Caenorhabditis elegans as a model organism for evaluating extracellular signal-regulated kinase docking domain inhibitors. J. Cell Commun. Signal. 2008, 2, 81-92.
86. Wesche, H.; Xiao, S. H.; Young, S. W. High throughput screening for protein kinase inhibitors. Comb. Chem. High Throughput Screen 2005, 8, 181-195.
87. von Ahsen, O.; Bomer, U. High-throughput screening for kinase inhibitors. Chembiochem 2005, 6, 481-490.
88. Minor, L. K. Assays to measure the activation of membrane tyrosine kinase receptors: Focus on cellular methods. Curr. Opin. Drug Discov. Devel. 2003, 6, 760-765.
89. Leavitt, S.; Freire, E. Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr. Opin. Struct. Biol. 2001, 11, 560-566.
90. Weber, P. C.; Salemme, F. R. Applications of calorimetric methods to drug discovery and the study of protein interactions. Curr. Opin. Struct. Biol. 2003, 13, 115-121.
91. Evans, L. J.; Labeit, S.; Cooper, A.; Bond, L. H.; Lakey, J. H. The central domain of colicin N possesses the receptor recognition site but not the binding affinity of the whole toxin. Biochemistry 1996, 35, 15143-15148.
92. Raggett, E. M.; Bainbridge, G.; Evans, L. J.; Cooper, A.; Lakey, J. H. Discovery of critical Tol A-binding residues in the bactericidal toxin colicin N: A biophysical approach. Mol. Microbiol. 1998, 28, 1335-1343.
93. Cooper, A.; Johnson, C. M.; Lakey, J. H.; Nollmann, M. Heat does not come in different colours: Entropy-enthalpy compensation, free energy windows, quantum confinement, pressure perturbation calorimetry, solvation and the multiple causes of heat capacity effects in biomolecular interactions. Biophys. Chem. 2001, 93, 215-230.
94. Malmqvist, M. Surface plasmon resonance for detection and measurement of antibody-antigen affinity and kinetics. Curr. Opin. Immunol. 1993, 5, 282-286.
95. Piliarik, M.; Vaisocherova, H.; Homola, J. Surface plasmon resonance biosensing. Methods Mol. Biol. 2009, 503, 65-88
96. Callaway, K.; Rainey, M. A.; Dalby, K. N. Quantifying ERK2-protein interactions by fluorescence anisotropy: PEA-15 inhibits ERK2 by blocking the binding of DEJL domains. Biochim. Biophys. Acta 2005, 1754, 316-323.
97. Reiner, D. J.; Gonzalez-Perez, V.; Der, C. J.; Cox, A. D. Use of Caenorhabditis elegans to evaluate inhibitors of Ras function in vivo. Methods Enzymol. 2008, 439, 425-449.
98. Artal-Sanz, M.; de Jong, L.; Tavernarakis, N. Caenorhabditis elegans: A versatile platform for drug discovery. Biotechnol. J. 2006, 1, 1405-1418.
99. Wu, Y.; Han, M. Suppression of activated Let-60 ras protein defines a role of Caenorhabditis elegans Sur-1 MAP kinase in vulval differentiation. Genes Dev. 1994, 8, 147-159.
100. Lackner, M. R.; Kornfeld, K.; Miller, L. M.; Horvitz, H. R.; Kim, S. K. A MAP kinase homolog, mpk-1, is involved in ras-mediated induction of vulval cell fates in Caenorhabditis elegans. Genes Dev. 1994, 8, 160-173.
101. Eliopoulos, A. G.; Dumitru, C. D.; Wang, C. C.; Cho, J.; Tsichlis, P. N. Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. EMBO J. 2002, 21, 4831-4840.
102. Diaz-Rodriguez, E.; Montero, J. C.; Esparis-Ogando, A.; Yuste, L.; Pandiella, A. Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: A potential role in regulated shedding. Mol. Biol. Cell 2002, 13, 2031-2044.